Objective: To observe the clinical efficacy of puerarin in treating patients with unstable angina (UA). Methods: Frequency of angina occurrences, consumed doses of nitrates, heart rate (HR), blood pressure, rest electrocardiogram (ECG) and myocardial oxygen consumption were observed before and after drug therapy in puerarin group (21 cases) and control group (18 cases) respectively. Results: The effect in the puerarin group not only showed to be better than that in the control group in reducing frequency of angina occurrence and consumed doses of nitrates, and improving abnormal rest ECG, but also appeared to be preferable to the control group in reducing myocardial oxygen consumption and increasing exercise duration ( P <0.05). Conclusion: Puerarin is a safe and effective drug in treating patients with UA.